MX2022014649A - Coctel de peptidos. - Google Patents
Coctel de peptidos.Info
- Publication number
- MX2022014649A MX2022014649A MX2022014649A MX2022014649A MX2022014649A MX 2022014649 A MX2022014649 A MX 2022014649A MX 2022014649 A MX2022014649 A MX 2022014649A MX 2022014649 A MX2022014649 A MX 2022014649A MX 2022014649 A MX2022014649 A MX 2022014649A
- Authority
- MX
- Mexico
- Prior art keywords
- peptide
- seq
- mutant protein
- amino acids
- consecutive amino
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 10
- 102000008300 Mutant Proteins Human genes 0.000 abstract 5
- 108010021466 Mutant Proteins Proteins 0.000 abstract 5
- 230000037433 frameshift Effects 0.000 abstract 5
- 150000001413 amino acids Chemical class 0.000 abstract 4
- 239000012634 fragment Substances 0.000 abstract 2
- 230000028993 immune response Effects 0.000 abstract 2
- 230000001939 inductive effect Effects 0.000 abstract 2
- 102100037936 Basic helix-loop-helix domain-containing protein USF3 Human genes 0.000 abstract 1
- 101000805924 Homo sapiens Basic helix-loop-helix domain-containing protein USF3 Proteins 0.000 abstract 1
- 101000923332 Homo sapiens Protein asteroid homolog 1 Proteins 0.000 abstract 1
- 102100032661 Protein asteroid homolog 1 Human genes 0.000 abstract 1
- 108091006740 SLC22A9 Proteins 0.000 abstract 1
- 102100035246 Solute carrier family 22 member 9 Human genes 0.000 abstract 1
- 230000002163 immunogen Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001103—Receptors for growth factors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001152—Transcription factors, e.g. SOX or c-MYC
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Genetics & Genomics (AREA)
- Microbiology (AREA)
- Zoology (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Se describe un péptido capaz de inducir una respuesta inmunitaria contra: una proteína mutante con cambio de marco -1a de ASTE1, en la que el péptido comprende al menos 10 aminoácidos consecutivos de la SEC ID NO: 26; una proteína mutante con cambio de marco -1a de ???1ß, en la que el péptido comprende al menos 10 aminoácidos consecutivos de la SEC ID NO: 27; una proteína mutante con cambio de marco -1a de KIAA2018, en la que el péptido comprende un fragmento inmunogénico de una de las SEC ID NO: 9-12, en la que el fragmento comprende al menos 8 aminoácidos consecutivos de una de las SEC ID NO: 9-12; o una proteína mutante con cambio de marco -1a de SLC22A9, en la que el péptido comprende al menos 8 aminoácidos consecutivos de una de las SEC ID NO: 14-18. También se describe una mezcla de péptidos que comprende un primer y un segundo péptidos, cada uno seleccionado independientemente de uno de los péptidos descritos anteriormente y un péptido capaz de inducir una respuesta inmunitaria contra una proteína mutante con cambio de marco -1a de ?T?ß?2.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP20177183 | 2020-05-28 | ||
PCT/EP2021/064415 WO2021239980A2 (en) | 2020-05-28 | 2021-05-28 | A peptide cocktail |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2022014649A true MX2022014649A (es) | 2022-12-15 |
Family
ID=70921797
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2022014649A MX2022014649A (es) | 2020-05-28 | 2021-05-28 | Coctel de peptidos. |
Country Status (12)
Country | Link |
---|---|
US (1) | US20230203130A1 (es) |
EP (1) | EP4157335A2 (es) |
JP (1) | JP2023529322A (es) |
KR (1) | KR20230019859A (es) |
CN (1) | CN115916251A (es) |
AU (1) | AU2021279327A1 (es) |
BR (1) | BR112022024074A2 (es) |
CA (1) | CA3179221A1 (es) |
CO (1) | CO2022018888A2 (es) |
IL (1) | IL298500A (es) |
MX (1) | MX2022014649A (es) |
WO (1) | WO2021239980A2 (es) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2022308403A1 (en) | 2021-07-09 | 2024-01-04 | Hubro Therapeutics As | A Primer |
WO2024052542A2 (en) | 2022-09-09 | 2024-03-14 | Hubro Therapeutics As | A peptide cocktail |
WO2024149791A1 (en) | 2023-01-11 | 2024-07-18 | Hubro Therapeutics As | A primer |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5866323A (en) | 1995-04-07 | 1999-02-02 | Case Western Reserve University | Cancer diagnosis prognosis and therapy based on mutation of receptors for transforming growth factor β and homologous growth controlling factors |
NO315238B1 (no) | 1998-05-08 | 2003-08-04 | Gemvax As | Peptider som stammer fra leserammeforskyvingsmutasjoner i TBF<beta>II- eller BAX-genet, og farmasöytiske sammensetninger inneholdende disse,nukleinsyresekvenser som koder for slike peptider, plasmider og virusvektoreromfattende slikenukleinsy |
WO2003087162A2 (en) | 2002-04-18 | 2003-10-23 | Mtm Laboratories Ag | Neopeptides and methods useful for detection and treatment of cancer |
ES2548391T3 (es) | 2011-09-21 | 2015-10-16 | Ruprecht-Karls-Universität Heidelberg | Péptidos de cambio de marco (FSP) específicos de MSI para prevención y tratamiento del cáncer |
KR101810840B1 (ko) | 2012-12-13 | 2017-12-20 | 루프레히트-칼스-유니페어지테트 하이델베르크 | 암의 예방 및 치료용 msi-특이적 프레임쉬프트 펩티드(fsp) |
US11484581B2 (en) * | 2017-06-02 | 2022-11-01 | Arizona Board Of Regents On Behalf Of Arizona State University | Method to create personalized canine cancer vaccines |
WO2018223093A1 (en) | 2017-06-02 | 2018-12-06 | Arizona Board Of Regents On Behalf Of Arizona State University | Universal cancer vaccines and methods of making and using same |
WO2019133853A1 (en) * | 2017-12-28 | 2019-07-04 | Gritstone Oncology, Inc. | Antigen-binding proteins targeting shared antigens |
EP3876971A4 (en) * | 2018-11-06 | 2023-01-11 | Icahn School of Medicine at Mount Sinai | PEPTIDES, COMPOSITIONS AND VACCINES FOR THE TREATMENT OF HYPERMUTATED TUMORS WITH MICROSATELLITE INSTABILITY AND METHODS OF USE THEREOF |
ES2970223T3 (es) | 2019-05-29 | 2024-05-27 | Hubro Therapeutics As | Péptidos |
-
2021
- 2021-05-28 CN CN202180038321.9A patent/CN115916251A/zh active Pending
- 2021-05-28 IL IL298500A patent/IL298500A/en unknown
- 2021-05-28 CA CA3179221A patent/CA3179221A1/en active Pending
- 2021-05-28 MX MX2022014649A patent/MX2022014649A/es unknown
- 2021-05-28 BR BR112022024074A patent/BR112022024074A2/pt unknown
- 2021-05-28 AU AU2021279327A patent/AU2021279327A1/en active Pending
- 2021-05-28 KR KR1020227044249A patent/KR20230019859A/ko active Search and Examination
- 2021-05-28 US US17/927,544 patent/US20230203130A1/en active Pending
- 2021-05-28 JP JP2022572641A patent/JP2023529322A/ja active Pending
- 2021-05-28 EP EP21729314.1A patent/EP4157335A2/en active Pending
- 2021-05-28 WO PCT/EP2021/064415 patent/WO2021239980A2/en active Application Filing
-
2022
- 2022-12-26 CO CONC2022/0018888A patent/CO2022018888A2/es unknown
Also Published As
Publication number | Publication date |
---|---|
IL298500A (en) | 2023-01-01 |
KR20230019859A (ko) | 2023-02-09 |
CO2022018888A2 (es) | 2022-12-30 |
WO2021239980A2 (en) | 2021-12-02 |
CN115916251A (zh) | 2023-04-04 |
EP4157335A2 (en) | 2023-04-05 |
US20230203130A1 (en) | 2023-06-29 |
JP2023529322A (ja) | 2023-07-10 |
BR112022024074A2 (pt) | 2022-12-20 |
CA3179221A1 (en) | 2021-12-02 |
AU2021279327A1 (en) | 2022-12-22 |
WO2021239980A9 (en) | 2022-05-27 |
WO2021239980A3 (en) | 2022-02-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2022014649A (es) | Coctel de peptidos. | |
MX2021014497A (es) | Peptidos. | |
EP1420821B8 (en) | Immunologically significant herpes simplex virus antigens and methods for using same | |
EP2258383A3 (en) | Antigenic peptides derived from telomerase | |
NZ570553A (en) | Immunogenic peptide sequences from influenza A and B and uses thereof for vaccines | |
ATE338121T1 (de) | Von muc-1 abgeleitete peptide | |
AR018603A1 (es) | Un peptido, util para el tratamiento y/o profilaxis de la enfermedad de alzheimer y el sindrome de down, las composiciones farmaceuticas y vacunas que locontienen, el uso de dicho peptido para la preparacion de las composiciones farmaceuticas, una secuencia de aislado de adn, un plasmido o vector vi | |
EP0962531A3 (en) | Interferon-gamma production inducing isolated polypeptide fragment and an isolated DNA fragment encoding said polypeptide | |
MX9503362A (es) | Nuevos anticuerpos br96 mutantes y equivalentes funcionales que reaccionan con carcinomas humanos. | |
EP0831900A4 (en) | METHOD FOR TRAINING ANTIBODIES AGAINST E. CS4CFA / 1 FAMILY PACKAGE | |
GB9606040D0 (en) | Active peptide | |
WO2004014937A3 (en) | Thrombin peptide derivatives | |
DE69836744D1 (de) | Gruppe a streptokokken-impfstoff | |
DE69121423D1 (de) | Rekombinante vakzine gegen coccidiose | |
GB0107319D0 (en) | Bacteriophage-mediated immunisation | |
WO2003090667A3 (fr) | Composition immunogene ou vaccinale non immunosuppressive, comprenant une proteine e7 mutee du virus hpv-16 | |
NZ508892A (en) | Nucleic acid encoding a vaccine-induced mutant major surface antigen of a hepatitis B viral strain | |
AU5776799A (en) | Modified hcv peptide vaccines | |
WO1996017059A3 (en) | Receptor for cell-binding domain of thrombospondins | |
NZ515041A (en) | Nucleic acid immunization | |
WO2024052542A3 (en) | A peptide cocktail | |
DE3751398D1 (de) | Substrat-Peptide. | |
Werner | Natural and synthetic peptides (other than neuropeptides) endowed with immunomodulating activities | |
GB2357507A (en) | Peptide fragments of cholera toxin B or enterotoxin B as vaccine adjuvants | |
CA2301333A1 (en) | Prb2/p130 peptide inhibitors of cdk2 kinase activity |